What Is Multiple Sclerosis?
People with MS are treated with medications and rehabilitation. Nine disease-modifying drugs are approved to treat multiple sclerosis. These drugs can help reduce the frequency and severity of relapses and slow disease progression and disability. Drugs approved by the Food and Drug Administration (FDA) are:
In 2014, the FDA approved a long-acting form of interferon beta-1a (Plegridy) to treat relapsing forms of MS. The medication is injected under the skin (subcutaneously) once every 2 weeks.
Complementary and Alternative Therapies
In 2014, the American Academy of Neurology (AAN) released guidelines for the use of complementary and alternative medicine (CAM) therapies in treating MS symptoms. Among the treatments that may be possibly effective:
Multiple sclerosis (MS) is a neurological disease that involves the central nervous system (CNS), the nerves that comprise the brain and spinal cord. The MS disease process has two main features:
Myelin is the layer that forms around nerves. Its purpose is to speed the transmission of impulses along nerve cells.
The symptoms, severity, and course of MS vary widely depending partly on the sites of the plaques and the extent of the demyelination.
Autoimmune Disease Process
Multiple sclerosis is thought to be an autoimmune disorder. In autoimmune diseases, immune factors attack the body’s own cells. In the case of MS, the immune system attacks the tissues that make up myelin. The damage to myelin, and nerve fibers (axons), is caused by over-active T cells. T cells are a type of white blood cell called lymphocytes.
Types of Multiple Sclerosis
Doctors generally group multiple sclerosis into four major disease course categories:
As with other autoimmune disorders, the exact cause of MS is unknown. A combination of environmental and genetic factors likely plays a role.
Multiple sclerosis is not hereditary, but genetic factors appear to make some people more susceptible to the disease. The most significant genetic link to MS occurs in the major histocompatibility complex (MHC), a cluster of genes on chromosome 6 that are essential for immune system function. A much smaller percentage of MS cases may be due to variations in interleukin-7 (IL-7) and interleukin-2 (IL-2) gene receptors, which are also related to immune system regulation.
Multiple sclerosis is more common in certain geographical areas of the world, particularly areas that are farther from the equator. Prevalence is generally highest in northern European and North American countries. The clustering of MS cases in these regions has led researchers to investigate whether certain toxins, infections, or vitamin deficiencies (such as vitamin D) may play a factor in triggering MS in genetically susceptible people.
Infectious organisms, mainly viruses, have long been suspects. They include Epstein-Barr virus (the cause of mononucleosis), herpesvirus 6, herpes simplex virus, influenza, measles, mumps, varicella-zoster virus, cytomegalovirus, respiratory syncytial virus, canine distempre virus, and Chlamydia pneumoniae. However, no direct link has been proven between these infections and multiple sclerosis. There is no evidence that any type of vaccination causes multiple sclerosis.
MS usually first appears between the ages of 20 and 50, with an average age of about 30. It rarely develops before age 15 or after age 60.
MS is about 2.5 times more common among women than men. The gender gap is strongest among people who develop MS at a younger age. However, some research indicates that men may be more disabled by the disease than women.
Race and Ethnicity
Multiple sclerosis occurs worldwide but is most common in Caucasian people of northern European origin, especially those of Scottish descent.
A family history of the disease may put some people at risk for MS, although the risk for someone inheriting all the genetic factors associated with MS is only about 2 to 4%. An identical twin of a person with MS has about a 25% chance of also developing MS. Some research indicates that family members who have MS tend to develop the disease at around the same age. However, family history does not predict whether one family member will experience the same disease severity as another family member.
Vitamin D Deficiency
Research suggests that low blood levels of vitamin D may increase the risk for developing MS, and for worsening the course of the disease in its early stages. Clinical trials are currently evaluating whether vitamin D supplements may help slow disease progression and improve clinical outcomes.
Vitamin D deficiency may partially explain why MS is less common in equatorial regions. People who live near the equator have an abundance of sun exposure and do not generally have vitamin D deficiency.
Possible Protective Factors
Estrogen and Oral Contraceptives. Higher estrogen levels may temporarily lower the risk of developing multiple sclerosis. Studies indicate that oral contraceptives (which contain estrogen) and pregnancy delay the onset of multiple sclerosis. The risk for a first clinical attack increases, however, in the first 6 months after a woman gives birth.
Multiple sclerosis is not a fatal disease. Except in rare cases of severe disease, most people with multiple sclerosis have a normal or near-normal life span and usually die from the same conditions (heart disease or cancer, for example) that affect the general population. Still, MS symptoms can negatively affect quality of life. Suicide rates among people with MS are higher than average.
The majority of people with MS do not become severely disabled. Twenty years after diagnosis, about two-thirds of people with MS remain ambulatory and do not need a wheelchair, although many of them may use a cane or crutches for walking assistance. Some people use an electric scooter or wheelchair to help cope with fatigue or balance problems.
The severity of the disease, and disease progression, varies widely from person to person and is unpredictable. About 20% of people remain asymptomatic or become only mildly symptomatic after an initial clinical event. Another 20% experience a rapidly progressive condition. Most people with MS will have some degree of disease progression. Women tend to have a better outlook than men.
Factors that determine a higher risk for a severe condition include:
Symptoms of multiple sclerosis appear in a variety of ways. Most people first have a single attack of symptoms, a neurological episode called a clinical isolated syndrome, which typically occurs between the ages of 20 and 50. Initial symptoms may be mild enough that people do not always seek medical care.
Once a second attack occurs, the person is considered to have relapsing-remitting multiple sclerosis. Much less commonly, the disease is progressive from the start, with more or less continuous symptoms.
Symptoms in multiple sclerosis depend on the location of the nerve lesion. Not all symptoms affect all people.
Symptoms more likely to occur earlier in the disease include:
Other Common Symptoms
Other common symptoms that progress over time include:
Bladder and Bowel Problems. Some people have problems emptying their bladder (urinary retention) and bowels (constipation) or find they cannot control their bladder and bowels (incontinence). People with urge incontinence need to urinate frequently or are unable to reach the bathroom before leakage occurs. Bladder problems, and catheterization for urinary retention, can lead to urinary tract infections.
Pain. Most people with MS have pain at some point during the course of the disease, and many are never completely pain free. MS causes many pain syndromes, which can last a short time or a long time. Some types of pain worsen with age and disease progression. Pain syndromes associated with MS include trigeminal neuralgia (facial pain), powerful spasms and cramps, pressure pain, stiffened joints, and a variety of sensations, including feelings of itching, burning, and shooting pain.
Sexual Dysfunction. Sexual dysfunction is a common problem. Men are likely to have erectile dysfunction, and women often have problems with vaginal lubrication. Sexual dysfunction appears to be highly associated with urinary dysfunction.
Speech and Swallowing Problems. Up to half of people with MS have trouble chewing or swallowing. Some people have slurred speech and problems speaking clearly.
Thinking, Concentration, and Memory Problems. Cognitive problems, such as having trouble concentrating, reasoning, and solving problems, affect many people with MS. Memory problems are common. These disabilities can create difficulties in the workplace.
Emotional and Psychiatric Problems.Depression is very common and is sometimes very severe. Depression can be caused both by lesions and physical changes in the brain as well as emotional response to the stress of dealing with MS. People with MS are also at risk for anxiety, bipolar, and psychotic disorders. Some people with severe MS have uncontrolled and extreme mood swings where they alternate between uncontrollable laughing and weeping (pseudobulbar affect).
Possible Symptom Triggers
MS flares (relapses) can be triggered by certain factors. Possible symptom triggers include:
Most people with MS first seek medical help after an initial attack of symptoms, called a clinically isolated syndrome (CIS). Not all people who have a CIS go on to develop MS, and it is difficult to predict who will or will not.
Multiple sclerosis can be challenging to diagnose as there is no single test for it, and a number of other conditions may mimic its symptoms. To confirm a diagnosis of multiple sclerosis the doctor needs to find:
A diagnosis of multiple sclerosis is based on results from a combination of various tests. They include medical history, neurological exam, magnetic resonance imaging (MRI) scans, evoked potential tests, and possibly a spinal fluid test.
The doctor will ask about your personal and family medical history, including lifestyle factors, prescription or other drug use, and other medical conditions that you or your relatives may have had. The doctor will ask you to describe your symptoms, when they occurred, and how long they lasted.
In a neurological exam, the doctor will test your vision and reflexes and evaluate balance, coordination, and muscle strength.
Evoked Potential (EP) Tests
The evoked potential (EP) test is a simple and painless electrical test of nerve function that assesses how long it takes nerve impulses from the eye, ear, or skin to reach the brain. It involves having electrodes placed on the scalp over specific areas of the brain that process sensory information. EP tests can be used to evaluate nerve transmission for vision, sound, or muscle responses in the legs or arms.
Magnetic Resonance Imaging
Magnetic resonance imaging (MRI) scans are important diagnostic tools in MS and are used for diagnosing multiple sclerosis, tracking changes over time, and helping to determine treatment effectiveness.
MRIs scans can detect bright patches that indicate areas of damaged myelin and injured tissue (lesions) caused by MS. However, about 5% of people who are confirmed to have multiple sclerosis based on other diagnostic criteria, do not show evidence of lesions in an initial MRI.
Once diagnosed, periodic follow-up MRIs can be used to track the disease and effectiveness of treatments in two ways:
Cerebrospinal Fluid Analysis
A spinal fluid test cannot by itself confirm or exclude multiple sclerosis but it can be useful when combined with other tests. Obtaining a sample of spinal fluid requires a lumbar puncture (also called spinal tap).
Spinal fluid in people with MS usually contains unusually high levels of immunoglobulin G (IgG) antibodies as well as other proteins and fragments of myelin. These can be signs of an autoimmune disorder, but not necessarily multiple sclerosis. About 90% of people with MS will have several types of these proteins (oligoclonal bands) in the spinal fluid, but not in the blood.
A lumbar puncture, or spinal tap, is a procedure to collect cerebrospinal fluid to check for the presence of disease or injury. A spinal needle is inserted, usually between the 3rd and 4th lumbar vertebrae in the lower spine. Once the needle is properly positioned in the subarachnoid space (the space between the spinal cord and its covering, the meninges), pressures can be measured and fluid can be collected for testing.
Ruling Out Other Disorders
The symptoms of MS overlap with a number of other diseases that must be ruled out. These conditions include stroke, alcoholism, emotional disorders, Lyme disease, chronic fatigue syndrome, fibromyalgia, AIDS, cervical spondylosis, other neurologic degenerative illnesses, transverse myelitis, and certain other autoimmune disorders (hypothyroidism, scleroderma, Sjögren syndrome, vasculitis, and systemic lupus erythematosus).
The goals of treatment for multiple sclerosis are to:
It is best to seek care from a neurologist experienced in treating multiple sclerosis.
Early Treatment. Evidence strongly suggests that the most destructive changes in the brain occur very early on in the MS disease process -- and may cause considerable damage even before symptoms begin.
Many doctors recommend treatment after a first neurological episode of MS (a clinically isolated syndrome) using disease-modifying drugs. The best current approach is to use specific findings from MRI scans to determine people at highest risk for progression, making them likely candidates for early treatment with these drugs.
Over a third of people will progress even with immediate treatment, but without early treatment about half of patients will progress to clinically identifiable multiple sclerosis.
Treatment with Disease-Modifying Drugs
Ten disease-modifying drugs are approved by the FDA for treatment of multiple sclerosis:
The interferon drugs (Betaseron, Extavia, Avonex, Rebif, and Plegridy) and glatiramer acetate (Copaxone) are given by self-injection at home. Natalizumab (Tysabri) and mitoxantrone (Novantrone) are given by intravenous infusion in a hospital or medical clinic setting. Fingolimod (Gilenya), teriflunomide (Aubagio), and dimethyl fumarate (Tecfidera) are taken by mouth as pills.
Most of these drugs are taken on a long-term basis. They can help reduce disease activity and progression for relapse-remitting MS (the most common form of MS) and other types of MS that have relapses (secondary-progressive MS, progressive-relapsing MS). At this time, there are no proven treatments for primary-progressive MS. Disease-modifying drugs can have significant side effects.
If disease-modifying drugs do not work, doctors may try other drugs that are not specifically approved for MS. They include intravenous immunoglobulin (IVIg), methotrexate, azathioprine (Imuran), and cyclophosphamide (Cytoxan).
Treating Acute Relapses
A relapse (also called exacerbation or flare-up) is an attack that brings about new symptoms or worsening of old symptoms. It is caused by inflammation in the central nervous system. Relapses can be mild or severe. They may last from a few days to several months.
Pseudoexacerbations are temporary worsening of symptoms that are usually caused by an external trigger, such as infection, heat, or stress. Pseudoexacerbations do not involve myelin inflammation and symptoms usually subside within 24 hours. To be considered a true relapse or exacerbation, symptoms and neurological signs must last at least 24 hours and occur at least 30 days after a previous attack.
Not all acute relapses require treatment. For attacks that are severe, a short course of high-dose corticosteroid drugs is the standard treatment. Typically, intravenous methylprednisolone (IVMP) is given for 3 to 5 days. Sometimes this is followed by oral prednisolone for a few days. Long-term treatment with corticosteroids is not recommended. These drugs can cause serious side effects and do not have any effect on MS disease progression.
Other treatment options for relapses are injections of adrenocorticotropic hormone (ACTH) and plasmapheresis (plasma exchange). These treatments are usually reserved for a small percentage of people with very severe symptoms who do not respond to steroid drugs.
MS symptoms are managed through a combination of treatment approaches that include medications, self-care, and physical and occupational therapy.
Drugs that are specifically approved for treating symptoms associated with MS include:
New Medications. New types of injectable and oral drugs for multiple sclerosis are currently being investigated in clinical trials.
Stem Cell Transplantation. Investigators are studying the possible benefits of stem cell transplantation procedures. Stem cells are produced in the bone marrow and are the early forms for all blood cells in the body (including red, white, and immune cells). Early studies indicate that stem cell transplantation may slow MS progression. Larger randomized controlled trials are currently under way.
Unproven Treatments. People with MS should be highly skeptical about treatments touted for MS that are unproven, have not been rigorously investigated, and have scant scientific evidence for safety or efficacy. For example, the FDA has warned of injuries and deaths associated with “liberation therapy.” This surgical procedure uses balloon angioplasty devices or stents to widen veins in the chest and neck associated with chronic cerebrospinal venous insufficiency (CCSVI).
The procedure has caused stroke, nerve damage, and death in several people. A research trial found the procedure did not help any study participants and worsened symptoms in several people. Studies have proven than CCSVI does not cause MS, and is not common in people with MS.
Interferon Beta Drugs
Interferons (so-called because they “interfere” with viral replication) suppress inflammatory factors in the immune system that are associated with the attack on myelin. Interferon drugs are the main treatments for relapsing-remitting MS. Doctors recommend that these medications be used early in the course of the disease and continued indefinitely, unless they produce no benefits or have severe side effects. When the drug is discontinued, disease activity may increase.
Brands. Interferon drugs used for MS are interferon beta-1b (Betaseron, Extavia) and interferon beta-1a (Avonex, Rebif, and Plegridy). They are the same chemical, but Avonex is given as weekly intramuscular injection, Rebif is injected subcutaneously (under the skin) 3 times a week, and Plegridy is injected subcutaneously once every 14 days.
Side Effects. Side effects include:
Neutralizing Antibodies That Reduce Effectiveness. Over time, people taking interferons develop antibodies to the drugs, some of which can neutralize their effects. The risk for neutralizing antibodies (NAbs) increases with higher doses and greater frequency of use. Interferons injected under the skin (Betaseron, Rebif) are more likely to produce neutralizing antibodies than Avonex, which is injected into a muscle.
People who have this reaction may be treated with an alternative interferon or with glatiramer, which has an extremely low risk, for NAbs. Often after switching drugs, NAb levels decline, and the patient may be able to return to the original interferon.
Glatiramer Acetate (Copaxone)
Glatiramer acetate (Copaxone) is a synthetic molecule that resembles a basic protein found in myelin. It is not known exactly how this medication works in treating MS. It may act as a decoy to trick white blood cells into attacking it instead of myelin. It may also affect the proportions of immune cells that promote or inhibit inflammation. Glatiramer acetate is approved to help reduce the frequency of relapses in people with relapse-remitting MS. It comes in pre-filled syringes and is given by subcutaneous (under the skin) injections.
The best results are for people in early stages of MS, but the longer the drug is used, the greater the improvement. Benefits may last for years. Glatiramer acetate appears to work as well as interferon beta drugs in decreasing the number and severity of relapses, but it may have less effect on lesions.
Side Effects. Side effects may occur right after the injection. They include pain at the injection site, chest pain, rapid heartbeat, flushing, anxiety, and shortness of breath.
Natalizumab (Tysabri) is a monoclonal antibody drug approved for treatment of MS. Monoclonal antibodies (MAbs) are immune proteins that have specific targets, including viruses, proteins, different cells and even other antibodies. Natalizumab targets a protein on white blood cells and may prevent them from attacking myelin.
Because of potentially serious side effects, natalizumab is often only given to people who have not responded to or who cannot tolerate other disease-modifying drugs, or to people who have a particularly aggressive course of MS. Natalizumab can only be taken alone, not in combination with other immune-modifying drugs. The drug is given by IV infusion once every 4 weeks
Many people who take natalizumab report great improvement in reduction of MS relapses and the drug appears to work well in slowing disease progression. However, natalizumab does carry risks for potentially serious side effects.
Common Side Effects. Common side effects include headache, fatigue, depression, joint pain, abdominal and chest discomfort, along with urinary tract, pneumonia, and other infections.
Severe Side Effects. People who take natalizumab must be monitored for signs of progressive multifocal leukoencephalopathy (PML). PML is a rare neurological disease that can affect people with compromised immune systems.
Three factors increase the risk for PML:
Symptoms of PML may include progressive weakness on one side of the body, clumsiness of limbs, vision disturbances, and changes in thinking, memory, and orientation that may result in confusion or personality changes. If PML is suspected, a magnetic resonance imaging (MRI) scan can confirm early stages of the disease. An MRI brain scan prior to starting natalizumab treatment can evaluate pre-existing brain lesions.
Natalizumab may cause liver damage. Signs of liver injury include yellowing of skin and eyes (jaundice), sudden darkening of urine, fatigue, and nausea and vomiting. You should immediately contact your doctor if any of these symptoms develop. If blood tests confirm liver injury, natalizumab should be discontinued.
Mitoxantrone (Novantrone) was the first drug approved specifically for secondary-progressive MS and progressive-relapsing MS. It is also used to treat worsening relapsing-remitting MS. Mitoxantrone is often used in combination with an interferon beta drug or glatiramer acetate.
Cumulative doses can have toxic effects on the heart, including heart failure, so the drug is only used for a limited period of 2 to 3 years. You should get a heart evaluation, including evaluation of left ventricular ejection fraction (LVEF), before starting this drug and before each dose administration. Mitoxantrone can also increase the risk for leukemia. Because several other treatments for MS with less toxicity are now available, mitoxantrone is not used as frequently these days.
Side Effects. In addition to risks of heart damage, common side effects of mitoxantrone include nausea, thinning hair, bladder infections, mouth sores, and loss of menstrual periods. This drug may cause a temporary bluish color to urine or eyes during the first 24 hours after IV infusion.
Fingolimod (Gilenya) was the first oral drug approved to treat relapsing forms of MS. [The other two oral drugs are teriflunomide (Aubagio) and dimethyl fumarate (Tecfidera).] Fingolimod is taken once-daily as a pill.
Common Side Effects. Common side effects may include headache, influenza, diarrhea, back pain, cough, and abnormal liver enzymes.
Severe Side Effects. Fingolimod can decrease heart rate (bradycardia, or bradyarrhythmia) especially after the first dose. (The health care provider should monitor the patient for 6 hours after the first dose to make sure there are no heart problems.) Heart rates usually stabilize within a month after starting fingolimod. Because of these cardiac side effects, people with certain pre-existing heart conditions or recent history of heart attack or stroke should not use fingolimod.
Other serious side effects include macular edema (fluid accumulation in a part of the eye’s retina), increased risk of serious infections, and shortness of breath. Fingolimod can cause liver problems so people should get liver tests before starting the drug. This drug may cause birth defects. Women of childbearing age who take fingolimod should use birth control while on the drug.
Teriflunomide (Aubagio) was the second approved oral treatment for relapsing forms of MS. Like fingolimod, teriflunomide is taken as a once-daily pill.
Common Side Effects. Teriflunomide may cause diarrhea, upset stomach, flu-like symptoms, and a burning sensation in skin. Hair thinning and loss may occur.
Severe Side Effects. Teriflunomide can cause serious liver problems and should not be taken by people with liver disease. The drug can lower white blood cell counts, which increases the risk for infections. Teriflunomide can affect a man’s sperm and it can cause birth defects in pregnant women. Both men and women who take teriflunomide should use contraception while taking this drug.
Dimethyl Fumarate (Tecfidera)
Dimethyl fumarate (Tecfidera) is the newest of the three oral drugs approved for treating relapsing forms of MS. Dimethyl fumarate is taken twice daily as a pill.
Common Side Effects. Like fingolimod and teriflunomide, this drug can cause upset stomach and diarrhea. This drug may also cause skin flushing and stomach pain.
Severe Side Effects. Dimethyl fumarate may lower white blood cell counts although it does not appear to seriously increase the risk for infections. It is uncertain if dimethyl fumarate causes birth defects or can be passed along in breast milk. This drug was approved in 2013, so its side effects may not yet be fully known.
Living with multiple sclerosis can be a challenging and frustrating experience. Fortunately, there are many different types of lifestyle changes and strategies that can help you better manage the symptoms and stresses of this disorder.
People with MS can benefit from various rehabilitation services to help them cope with physical and emotional symptoms:
Assistive Devices and Adaptive Tools
In addition to electric scooters and other mobility devices, there are many devices that can make life easier in the home. They include:
Fatigue is very common in multiple sclerosis and it can worsen as the day progresses. It is important to get sufficient rest and to develop strategies (and priorities) for conserving energy. An occupational or physical therapist can advise you on ways to make walking and daily household tasks less tiring. Assistive devices can be very helpful. If you have problems with sleep, or bladder problems are interfering with your sleep, talk with your doctor about possible medications or other therapies.
Body Temperature Control
Raised body temperature often triggers symptoms of MS. The following measures may help:
People with MS should try to engage in a variety of exercises including stretching, muscle strengthening, and range-of-motion. Exercise can help reduce fatigue and relieve muscle spasticity, and it can help your mind and spirit as well as your body. A physical therapist can suggest exercise programs that are best for you, and help set realistic goals.
Many people with MS find water a great environment for exercise. In addition to swimming, there are various types of aquatic exercises that can help improve balance, strength, and stretching. People with MS should take caution with exercises that raise body temperature, which can temporarily worsen symptoms.
A healthy diet is very important for keeping your heart, bones, and immune system strong. Eating right will also help control your weight (a concern for many patients with MS) and help with fatigue. Some dietary suggestions include:
It is important to find strategies to deal with the stress of living with a chronic and unpredictable condition. Many people with MS struggle with feelings of anger, depression, and a sense of loss of control. Some people find that stress can worsen MS symptoms such as fatigue.
Stress management techniques include deep breathing and other relaxation modalities, meditation, biofeedback, music therapy, yoga, tai chi, and massage therapy. Exercise is also an excellent way to reduce stress. Building a strong and positive support network of family and friends can also help you better deal with stress.
MS symptoms worsen during a cold or the flu, probably because of increased immune system activity and fever. People with MS should receive a flu shot in the fall. However, they should not take the nasal spray version of the flu vaccine (FluMist Intranasal). Unlike the flu injection vaccine, which uses an inactivated virus, FluMist contains a live virus. Live virus vaccinations may be harmful for people with MS, especially those who take immune-suppressing drugs.
Reflexology involves placing pressure to specific areas of the feet or hands that are thought to correspond to parts of the body. Based on limited studies, the American Academy of Neurology (AAN) considers reflexology as possibly effective for reducing the "pins and needles" sensations (paresthesia) experienced by some people with MS. Paresthesia is characterized by tingling, prickling, or burning sensations in the hands, feet, legs, or arms.
Pulsed magnetic therapy may possibly help with MS fatigue symptoms, but not depression, according to the AAN guidelines.
Herbs and Supplements
Generally, manufacturers of herbal remedies and dietary supplements do not need FDA approval to sell their products. Just like a drug, herbs and supplements can affect the body's chemistry, and therefore have the potential to produce side effects that may be harmful. There have been a number of reported cases of serious and even lethal side effects from herbal products. Check with your health care provider before using any herbal remedies or dietary supplements.
The following are some popular herbal and supplement remedies for multiple sclerosis:
www.ninds.nih.gov -- National Institute of Neurological Disorders and Stroke
www.aan.com -- American Academy of Neurology
www.msassociation.org -- Multiple Sclerosis Association of America
www.nationalmssociety.org -- National Multiple Sclerosis Society
www.msfocus.org -- Multiple Sclerosis Foundation
www.abledata.com -- National database of assistive devices and rehabilitation equipment
Amatya B, Khan F, La Mantia L, Demetrios M, Wade DT. Non pharmacological interventions for spasticity in multiple sclerosis. Cochrane Database Syst Rev. 2013;2:CD009974.
Ascherio A, Munger KL, White R, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol. 2014;71(3):306-314.
Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870-1880.
Calabresi P. Multiple sclerosis and demyelinating conditions of the central nervous system. In: Goldman L, Ausiello D, eds. Cecil Medicine. 24th ed. Philadelphia, Pa: Saunders Elsevier; 2012:chap 419.
Farinotti M, Vacchi L, Simi S, Di Pietrantonj C, Brait L, Filippini G. Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev. 2012;12:CD004192.
Filippini G, Del Giovane C, Vacchi L, et al. Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2013;6:CD008933.
Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;71(10):766-773.
Houtchens MK, Lublin FD, Miller AE, Khoury SJ. Multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system. In: Daroff RB, Fenichel GM, Jankovic J, Mazziotta JC, eds. Bradley’s Neurology in Clinical Practice. 6th ed. Philadelphia, Pa: Saunders Elsevier; 2012:1283-1313.e2.
International Multiple Sclerosis Genetics Consortium, Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genome wide study. N Engl J Med. 2007;357(9):851-862.
Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(17):1556-1563.
Kuehn BM. FDA warns about the risks of unproven surgical therapy for multiple sclerosis. JAMA. 2012;307(24):2575-2576.
Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;74(18):1463-1470.
Minden SL, Feinstein A, Kalb RC, et al. Evidence-based guideline: assessment and management of psychiatric disorders in individuals with MS: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82(2):174-181.
O'Gorman C, Lin R, Stankovich J, Broadley SA. Modelling genetic susceptibility to multiple sclerosis with family data. Neuroepidemiology. 2013;40(1):1-12.
Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med. 2012;366(4):339-347.
Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
Traboulsee AL, Knox KB, Machan L, et al. Prevalence of extracranial venous narrowing on catheter venography in people with multiple sclerosis, their siblings, and unrelated healthy controls: a blinded, case-control study. Lancet. 2014;383(9912):138-145.
Yadav V, Bever C Jr, Bowen J, et al. Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014;82(12):1083-1092.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.